Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services

Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services 
WINNIPEG, MANITOBA -- (Marketwired) -- 04/14/14 -- Medicure Inc.
("Medicure" or the "Company") (TSX VENTURE:MPH)(OTCQB:MCUJF), a
specialty pharmaceutical company, today announced it has entered into
an arrangement with Knight Therapeutics Inc. (TSX VENTURE:GUD), under
which Knight will provide advisory services to help advance
Medicure's U.S. specialty pharmaceutical business and corporate
development initiatives.  
"Medicure is pleased to have the opportunity to work with Jonathan
Ross Goodman, co-founder of Paladin Labs Inc. and CEO of Knight
Therapeutics Inc." stated Dr. Albert D. Friesen, CEO and Chair of
Medicure Inc. "We look forward to benefitting from the depth of
experience and networks that he has built up in establishing and
growing a successful specialty pharmaceutical business." 
Jonathan Ross Goodman, CEO of Knight Therapeutics Inc. commented, "I
am pleased to leverage my skills and experience to help Medicure
further grow its business."  
About Knight Therapeutics 
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a
specialty pharmaceutical company focused on acquiring or in-licensing
innovative pharmaceutical products for the Canadian and world
markets. Knight Therapeutics' shares began trading on the TSX-V on
March 3, 2014 under the symbol GUD. For more information about Knight
Therapeutics, please visit the company's web site at
www.gud-knight.com or at www.sedar.com  
About Medicure Inc.  
Medicure is a specialty pharmaceutical company focused on the
development and commercialization of novel small molecule
therapeutics. The primary focus of the Company and its subsidiaries
is the marketing and distribution of AGGRASTAT (tirofiban HCl) for
non-ST elevation acute coronary syndrome in the United States, where
it is sold through the Company's U.S. subsidiary, Medicure Pharma,
Inc. For more information on Medicure please visit www.medicure.com.  
To be added to Medicure's e-mail list, please visit:
http://medicure.com/newsreleases.html  
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. Forward
Looking Information Statements contained in this press release that
are not statements of historical fact, including, without limitation,
statements containing the words "believes", "may", "plans", "will",
"estimates", "continues", "anticipates", "intends", "expects" and
similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal securities
laws (such forward-looking information and forward-looking statements
are hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, including the potential for
Medicure to attain material benefit from the advisory services of
Knight Therapeutics, are based on the current assumptions, estimates,
analysis and opinions of management of the Company made in light of
its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances. Inherent
in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements.  
Such risk factors include, among others, the Company's future product
revenues, stage of development, additional capital requirements,
risks associated with the completion and timing of clinical trials
and obtaining regulatory approval to market the Company's products,
the ability to protect its intellectual property, dependence upon
collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in the
industry. Such statements are based on a number of assumptions which
may prove to be incorrect, including, but not limited to, assumptions
about: general business and economic conditions; the impact of
changes in Canadian-US dollar and other foreign exchange rates on the
Company's revenues, costs and results; the timing of the receipt of
regulatory and governmental approvals for the Company's research and
development projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; results of current
and future clinical trials; the uncertainties associated with the
acceptance and demand for new products and market competition. The
foregoing list of important factors and assumptions is not
exhaustive. The Company undertakes no obligation to update publicly
or otherwise revise any forward-looking statements or the foregoing
list of factors, other than as may be required by applicable
legislation. Additional discussion regarding the risks and
uncertainties relating to the Company and its business can be found
in the Company's other filings with the applicable Canadian
securities regulatory authorities or the US Securities and Exchange
Commission, and in the "Risk Factors" section of its Form 20F for the
year ended May 31, 2013. 
Contacts:
Medicure Inc.
Dawson Reimer
President & COO
888-435-2220
204-488-9823 (FAX)
info@medicure.com
www.medicure.com
 
 
Press spacebar to pause and continue. Press esc to stop.